- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06938412
Intervention der Übungsaktivität mit sensorbasiertem Engagement bei Patienten mit Vorhofflimmern (EASE-AF)
Intervention der Übungsaktivität mit sensorbasiertem Engagement bei Patienten mit Vorhofflimmern (Easy-AF)
Atrial fibrillation (AF) affects 1 in 4 individuals during their lifetime and continues to increase in frequency and impact. Exercise intervention has established benefits to improve AF symptoms and burden in clinical studies. However, lack of access to exercise programs has limited therapeutic adoption. The growth of technology-driven health care and diagnostics, recognized as an emerging priority by the American Heart Association, offers an opportunity for a pragmatic and patient-centered approach to meet this need. EASE-AF is a prospective, interventional study with a sequential run-in control to evaluate if a digital health-driven, patient-centered exercise intervention improves AF symptoms and burden. The research team will enroll 120 patients with symptomatic, non-permanent AF. The main impact of this study will be the establishment of evidence for a novel, pragmatic paradigm for a patient-centered, digital technology-driven personalized exercise intervention for patients with AF.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Jaclyn Printz
- Telefonnummer: 917-991-674
- E-Mail: EASE-AF@mountsinai.org
Studieren Sie die Kontaktsicherung
- Name: Jaclyn Printz
- Telefonnummer: 212-824-7077
- E-Mail: Jaclyn.Printz@mountsinai.org
Studienorte
-
-
New York
-
New York, New York, Vereinigte Staaten, 10029
- Rekrutierung
- Icahn School of Medicine at Mount Sinai
-
Hauptermittler:
- Janice Y Chyou, MD
-
Kontakt:
- Jaclyn Printz
- E-Mail: EASE-AF@mountsinai.org
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- ≥40years of age
- non-permanent AF
- Electrocardiographic (or equivalent) documentation of AF within 36 months (would need to have evidence of AF after initial post-ablation blanking period if the patient had prior AF ablation)
- AF Severity Scale (AFSS) symptom score 6-26
- Self-report weekly moderate-vigorous physical activity (MVPA) < 150 minutes
Exclusion Criteria:
- Unable to give consent
- ≤90 days from AF ablation, coronary revascularization, heart failure hospitalization
- Left ventricular ejection fraction (LVEF) <40%, moderate to severe stenotic valvular heart disease or severe regurgitant valvular disease or history of mechanical valve replacement, presence of implanted pacemaker or defibrillator system
- Labile INR or unable to take anticoagulant despite indication
- Life expectancy < 1 year
- Hemodialysis; severe pulmonary or liver disease
- Musculoskeletal, balance/gait issues, severe peripheral vascular disease, or neuropathy or other neurologic conditions limiting exercise
- Upon initial screening, if the participant's baseline FitBit-measured MVPA ≥180 minutes/week (despite self-report range of <150 minutes), the participant will be further excluded.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Patients With Atrial Fibrillation
Patients with symptomatic, non-permanent AF. |
The intervention is a digital technology-driven, patient-centric approach to physical activity and exercise intervention with tailored digital engagement and progressive physical activity goals (the intervention). The intervention will be conducted using FitBit wearable device. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Atrial Fibrillation Severity Scale (AFSS), Symptom Severity Domain
Zeitfenster: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
The Symptom Severity domain (Part C) of the validated Atrial Fibrillation Severity Scale (AFSS) questions patients regarding the severity of 7 AF-related symptoms (on scale of 0-5 per question, 5 denoting a great deal of symptom and 0 with no symptom) over the preceding 4-week period. Total scores range 0-35 on the Symptom Severity Domain of the Atrial Fibrillation Severity Scale (AFSS), higher score denotes more severe AF-related symptoms. |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Atrial Fibrillation Severity Scale (AFSS)
Zeitfenster: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
The full Atrial Fibrillation Severity Scale (AFSS) is composed of 19-items, investigating four domains: global well-being, symptom burden, health care utilization, symptom severity. Global well-being: 1-10; 10 denotes best possible quality of life. Symptom burden: Composite of AF burden as AF duration + AF frequency + AF severity; ranging 0-30, higher denotes more symptom burden. Health care utilization: ER visits (0-7, higher number denotes more utilization), Hospitalizations (0-7, higher number denotes more utilization), Specialist visits (0-7, higher number denotes more utilization); Symptom Severity: 0-35, higher score denotes more severe AF-related symptoms |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
AF Arrhythmia Burden: Percentage of time in AF
Zeitfenster: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Global AF arrhythmia burden will be measured as percentage of time in AF measured during an 8-14-day monitoring period at the end of each time point as quantified by either clinically validated patch-based monitoring system or loop recorder. |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
AF Arrhythmia Burden: Duration of longest AF Arrhythmia Episode
Zeitfenster: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Duration of the longest AF episode during the monitoring period will be quantified by either clinically validated patch-based monitoring system or loop recorder. |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
Weekly Step Counts
Zeitfenster: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Weekly step counts measured by FitBit wearable device provided by the study |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
Weekly Exercise Minutes
Zeitfenster: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Weekly exercise minutes measured by FitBit wearable device provided by the study |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Janice Y Chyou, MD, Icahn School of Medicine at Mount Sinai
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- STUDY-24-00464
- 24SCEFIA1249819 (Andere Zuschuss-/Finanzierungsnummer: American Heart Association)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Not planning to share individual participant data. Aggregate data will be shared instead.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .